Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH

Abstract Sodium glucose cotransporter 2 (SGLT2) inhibitors, an antidiabetic drug, promotes urinary excretion of glucose by blocking its reabsorption in the renal proximal tubules. It is unclear whether SGLT2 inhibition could attenuate nonalcoholic steatohepatitis (NASH) and NASH-associated hepatocel...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Kumiko Shiba, Kyoichiro Tsuchiya, Chikara Komiya, Yasutaka Miyachi, Kentaro Mori, Noriko Shimazu, Shinobu Yamaguchi, Naomi Ogasawara, Makoto Katoh, Michiko Itoh, Takayoshi Suganami, Yoshihiro Ogawa
Format: article
Langue:EN
Publié: Nature Portfolio 2018
Sujets:
R
Q
Accès en ligne:https://doaj.org/article/f40c5869250d4118846a58308f7da1f5
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!